(R)-2-HG - a-KG-dependent dioxygenases inhibitor. CAS# 103404-90-6 60225 32)30-7-5-28(6-8-30)15-16-13-20-21(34-16)23(29-9-11-33-12-10-29)26-22(25-20)17-3-2-4-19-18(17)14-24-27-19/h2-4

32)30-7-5-28(6-8-30)15-16-13-20-21(34-16)23(29-9-11-33-12-10-29)26-22(25-20)17-3-2-4-19-18(17)14-24-27-19/h2-4

J Clin Virol

Smiles: C(C1C=CC=CC=1)N1C(=NC2=CC=CC=C12)C1C=CC(=CC=1)OC[C@H](C1CCNCC1)N1C(=NC2=CC=CC=C12)C1C=CC=CC=1

EZH2 inhibitor efficacy in non-Hodgkin's lymphoma does not require suppression of H3K27 monomethylation

(R)-2-HG - a-KG-dependent dioxygenases inhibitor. CAS# 103404-90-6 60225 32)30-7-5-28(6-8-30)15-16-13-20-21(34-16)23(29-9-11-33-12-10-29)26-22(25-20)17-3-2-4-19-18(17)14-24-27-19/h2-4Mutations, CAS No. 103404 90 6, in IDH1 and IDH2, the genes coding for isocitrate dehydrogenases 1 and 2, are common in several human cancers, such as leukemia and glioma, and result in overproduction of the (R) enantiomer of 2 hydroxyglutarate [(R) 2 HG]. Elucidation of the role of IDH mutations and (R) 2 HG in leukemogenesis has been hampered by a lack of appropriate cell based models. It has been recently reported that a canonical IDH1 mutant, IDH1